Literature DB >> 21641214

Flavonoids as inhibitors of human CD38.

Esther Kellenberger1, Isabelle Kuhn, Francis Schuber, Hélène Muller-Steffner.   

Abstract

CD38 is a multifunctional enzyme which is ubiquitously distributed in mammalian tissues. It is involved in the conversion of NAD(P)(+) into cyclic ADP-ribose, NAADP(+) and ADP-ribose and the role of these metabolites in multiple Ca(2+) signaling pathways makes CD38 a novel potential pharmacological target. The dire paucity of CD38 inhibitors, however, renders the search for new molecular tools highly desirable. We report that human CD38 is inhibited at low micromolar concentrations by flavonoids such as luteolinidin, kuromanin and luteolin (IC(50) <10 μM). Docking studies provide some clues on the mode of interaction of these molecules with the active site of CD38.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641214     DOI: 10.1016/j.bmcl.2011.05.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  36 in total

1.  Characterization of CD38 in the major cell types of the heart: endothelial cells highly express CD38 with activation by hypoxia-reoxygenation triggering NAD(P)H depletion.

Authors:  James Boslett; Craig Hemann; Fedias L Christofi; Jay L Zweier
Journal:  Am J Physiol Cell Physiol       Date:  2017-11-29       Impact factor: 4.249

2.  CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells.

Authors:  Ilaria Schiavoni; Carolina Scagnolari; Alberto L Horenstein; Pasqualina Leone; Alessandra Pierangeli; Fabio Malavasi; Clara M Ausiello; Giorgio Fedele
Journal:  Immunology       Date:  2017-12-18       Impact factor: 7.397

3.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

Review 4.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

Review 5.  Modulating NAD+ metabolism, from bench to bedside.

Authors:  Elena Katsyuba; Johan Auwerx
Journal:  EMBO J       Date:  2017-08-07       Impact factor: 11.598

6.  Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model.

Authors:  Eran Blacher; Tulin Dadali; Alina Bespalko; Viola J Haupenthal; Marcus O W Grimm; Tobias Hartmann; Frances E Lund; Reuven Stein; Ayelet Levy
Journal:  Ann Neurol       Date:  2015-05-25       Impact factor: 10.422

Review 7.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

8.  Inhibition of CD38 with the Thiazoloquin(az)olin(on)e 78c Protects the Heart against Postischemic Injury.

Authors:  James Boslett; Nikhil Reddy; Yasmin A Alzarie; Jay L Zweier
Journal:  J Pharmacol Exp Ther       Date:  2019-01-11       Impact factor: 4.030

9.  Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H).

Authors:  James Boslett; Craig Hemann; Yong Juan Zhao; Hon-Cheung Lee; Jay L Zweier
Journal:  J Pharmacol Exp Ther       Date:  2017-01-20       Impact factor: 4.030

10.  Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPKα1/SIRT1.

Authors:  Jing Dong; Xian Zhang; Lei Zhang; Hui-Xi Bian; Na Xu; Bin Bao; Jian Liu
Journal:  J Lipid Res       Date:  2014-01-24       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.